XNCR News and Press, Xencor Inc. From 11/07/22

-- XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study -- -- Management to host conference call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-s...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecif...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2022 financial results after the market closes on Monday, November 7,...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, be...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to its board of directors. Dr. Valente has more than 20 year...

Xencor ( NASDAQ: XNCR ) is trading 7% lower after the company posted Q2 result that missed estimates, due to lower royalty revenues. Revenue fell 55.3% Y/Y to  $30.18M, and missed estimates by $3.83M, while Q2 GAAP EPS of -$0.57 missed by $0.10. R...

Xencor, Inc. (XNCR) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President and CEO Allen Yang - CMO John Kuch - CFO John Desjarlais - CSO Con...

Xencor press release ( NASDAQ: XNCR ): Q2 GAAP EPS of -$0.57 misses by $0.10 . Revenue of $30.18M (-55.3% Y/Y) misses by $3.83M . “Later this year, we plan to present additional clinical data from our vudalimab and plamotamab programs and initial data fr...

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the seco...

Clinical-stage biotech Xencor, Inc. ( NASDAQ: XNCR ) and Irving, Texas-based molecular science company Caris Life Sciences unveiled a multi-year agreement on Tuesday to develop and commercialize XmAb bispecific antibodies targeted for the treatment of cancer patients. Per ...